NCT01789827View on ClinicalTrials.gov

Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 27, 2018

Study Completion Date

June 27, 2018

Conditions
Stage IV Skin Melanoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Radionuclide Imaging

Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies

BIOLOGICAL

Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2

Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER